Work

The p53/MDM2/MDMX-targeted therapies—a clinical synopsis

Year: 2020
Type: article
Abstract: The cost of cancer care accelerates because of the growing number of cancer patients and the increasing expenses of drug innovations. The approval of costly second-line therapies like immune checkpoint inhibitors or CAR-T therapies contributes to this trend. Hence, drug repurposing, which uses drugs originally approved for other indications, is emerging as a necessary approach in cancer care, due to its comparatively low innovation and treatment costs and predictable side-effects 1 .
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,990
OpenAlex ID: W3016812120
FWCI: 4.342
Cites: 19
Cited by: 68
Related to: 10